Peptron Inc
Peptron Inc is a South Korean biotechnology and medical research company that develops and commercializes diagnostic and therapeutic products, primarily in the life sciences tools and services sector.
Business. Peptron Inc (087010.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Peptron Inc (087010.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Peptron Inc's capital structure is characterized by a debt-to-equity ratio of 0.21, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 16.45, suggesting strong short-term liquidity. However, the company's cash and equivalents of 4,377,757,820 KRW are insufficient to cover its long-term debt of 29,555,360,280 KRW, resulting in a net cash position that is negative after subtracting total debt.
Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of 13,823,782,610 KRW and an operating loss of 21,257,384,880 KRW, with a return on equity of -9.73% and a return on assets of -7.72%. These figures indicate a company in distress, with negative returns on both equity and total assets.
Geographically, Peptron Inc's revenue is concentrated in South Korea, as disclosed in its segments. The company's exposure to a single geographic market increases its vulnerability to local economic and regulatory shifts. No specific segment breakdown is available in the provided data, but the company's primary operations are in the life sciences tools and services sector.
The company's growth trajectory is negative, with a reported revenue of 5,634,817,680 KRW, significantly below the analyst estimate of 3,120,700,000 KRW. The operating cash flow is negative at -20,586,335,440 KRW, and the free cash flow is also negative at -14,105,420,950 KRW. These figures suggest a lack of operational cash generation and a need for external financing to sustain operations.
Risk factors include a high probability of liquidity stress, as the company's cash and equivalents are insufficient to cover its long-term obligations. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. However, the negative operating and free cash flows suggest a potential need for future capital raising, which could lead to dilution.
Recent events include the company's reported financial results, which show a significant decline in profitability and liquidity. The company's operating cash flow and free cash flow are both negative, indicating a need for external financing. No recent filings or transcripts are available in the provided data, but the company's financial performance suggests a challenging operating environment.
- Peptron Inc is experiencing significant financial distress, with large operating and net losses.
- The company's liquidity is medium, but its cash and equivalents are insufficient to cover long-term debt.
- Profitability metrics are negative, with a return on equity of -9.73% and a return on assets of -7.72%.
- The company's revenue is concentrated in South Korea, increasing its exposure to local market risks.
- The company's growth trajectory is negative, with reported revenue below analyst estimates.
- The risk assessment indicates a medium liquidity risk and a low dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Peptron Inc Market data — financials · 2026-05-26
- Peptron Inc Market data — analyst estimates · 2026-05-26